exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • Wezlana

    • Drug: Wezlana (ustekinumab-auub)
    • Manufacturer: Amgen

    • Route of Administration: Intravenous, Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

      • treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
      • treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older
      • treatment of moderately-to-severely active Crohn’s disease in adults
      • treatment of moderately-to-severely active ulcerative colitis in adults

    • Disease: Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: N/A
    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: N/A

  • Winrevair

    • Drug: Winrevair (sotatercept)
    • Manufacturer: Merck
    • Route of Administration: Subcutaneous
    • Site of Care: Outpatient

    • Approved Indication: treatment of adults with pulmonary arterial hypertension (PAH, WHO group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events

    • Disease: pulmonary arterial hypertension

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: Merck Access Program – Winrevair
    • Phone Number: 888-637-2502
    • Fax Number: 877-219-7579
    • Product Website: winrevair.com

  • Xeljanz

    • Drug: Xeljanz (tofacitinib)
    • Manufacturer: Pfizer

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication:

        • treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
        • treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
        • treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
        • treatment of adult patients with moderately-to-severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers
        • treatment of active polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers
    • Disease: atopic dermatitis, ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: XELSOURCE
    • Phone Number: 1-844-935-5269
    • Fax Number: 1-866-297-3471
    • Product Website: xeljanz.com

  • Xphozah

    • Drug: Xphozah (tenapanor)
    • Manufacturer: Ardelyx

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy

    • Disease: chronic kidney disease
    • Therapeutic Area: Nephrology
    • Enrollment Form Link: xphozah-hcp.com/prescribe
    • Phone Number: 877-527-3927
    • Fax Number: 877-594-4906
    • Product Website: xphozah.com

  • Yuflyma

    • Drug: Yuflyma (adalimumab-aaty)
    • Manufacturer: Celltrion

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adult patients
        • treatment of moderately to severely active ulcerative colitis in adult patients
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in adult patients
        • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.yuflyma.com/support

    • Phone Number: 1-877-81CONNC (1-877-812-6662)
    • Fax Number: 614-633-2259

    • Product Website: yuflyma.com

  • Yusimry

    • Drug: Yusimry (adalimumab-aqvh)
    • Manufacturer: Coherus

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adult patients
        • treatment of moderately to severely active ulcerative colitis in adult patients
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in adult patients
        • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: patient.yusimry.com/cost

    • Phone Number: 1-800-YUSIMRY (1-800-987-4679)
    • Fax Number: 1-800-987-9888
    • Product Website: yusimry.com

  • Yutrepia

    • Drug: Yutrepia (treprostinil)
    • Manufacturer: Liquidia
    • Route of Administration: Inhalation
    • Site of Care: Outpatient

    • Approved Indication:

      • pulmonary arterial hypertension (WHO group 1) to improve exercise ability
      • pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO group 3) to improve exercise ability
    • Disease: pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD)

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: Enrollment Form
    • Phone Number: N/A
    • Fax Number: N/A

    • Product Website: yutrepia.com

  • Zenpep

    • Drug: Zenpep (pancrelipase)

    • Manufacturer: Nestlé

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of exocrine pancreatic insufficiency in adult and pediatric patients

    • Disease: exocrine pancreatic insufficiency

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A

    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: zenpep.com

  • Zepatier

    • Drug: Zepatier (elbasvir/grazoprevir)
    • Manufacturer: Merck

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of adults with chronic HCV genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis in combination with ribavirin for certain patient populations

    • Disease: chronic viral hepatitis C

    • Therapeutic Area: Infectious disease, Gastroenterology, Hepatology

    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A

    • Product Website: N/A

  • Zeposia

    • Drug: Zeposia (ozanimod)
    • Manufacturer: Bristol Myers Squibb

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication:

        • treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
        • treatment of moderately-to-severely active ulcerative colitis in adults
    • Disease: multiple sclerosis, ulcerative colitis
    • Therapeutic Area: Gastroenterology, Neurology
    • Enrollment Form Link: N/A
    • Phone Number: 1-833-ZEPOSIA (1-833-937-6742)
    • Fax Number: 1-833-727-7701
    • Product Website: zeposia.com